The FDA’s Antimicrobial Drugs Advisory Committee will meet Wednesday, August 7, to review and discuss Gilead’s (NASDAQ:GILD) marketing application for Descovy (emtricitabine and tenofovir alafenamide) for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV infection.
In the FDA’s summary, it stated that trial data from the DISCOVER study demonstrated Descovy’s non-inferiority to Truvada.
Shares are down 1% premarket on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.